Y-mAbs Announces Publication in Cancers
“The publication in Cancers further validates the utilization of naxitamab early during the course of treatment for patients with high-risk neuroblastoma,” said Thomas Gad, Founder, President and Interim Chief Executive Officer.
- “The publication in Cancers further validates the utilization of naxitamab early during the course of treatment for patients with high-risk neuroblastoma,” said Thomas Gad, Founder, President and Interim Chief Executive Officer.
- Cycles were administered 3-5 weeks apart and the primary endpoint was overall response rate (CR + partial response (“PR”)).
- The HITS combination did not appear to exacerbate the rate nor the intensity of infusion-related toxicities of naxitamab when observed as a stand-alone treatment.
- Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed DANYELZA® (naxitamab-gqgk), which is exclusively licensed by MSK to Y-mAbs.